Today, the ingestible sensor is integrated inside inactive pills that are taken alongside medication. In the future, the ingestible sensor will be integrated directly inside active pharmaceuticals in select therapeutic areas
Digital Medicines are under development and are not yet FDA cleared. We have conducted clinical trials in these therapeutic areas:
Heart failure is a challenging condition that often results in hospitalization. Currently, close to one quarter of all heart failure patients are re-admitted within 30-days of discharge due to complications and difficulty following their challenging new care regimens. We hope that digital medicines will help heart failure patients stay in control, in better communication with their clinicians, and safely in the comfort of their own homes.
Central Nervous System
Diseases of the central nervous system (including multiple sclerosis, Huntington’s, schizophrenia, Parkinson’s and Alzheimer’s) present a variety of challenges to both adherence and health tracking. People suffering from these conditions have to maintain very strict health regimens to keep their conditions under control.
We are exploring ways to help transplant patients who take medicines that suppress their immune systems. Given the inherent risk in suppressing immune response, tracking both adherence and basic health parameters using digital medicines may have a significant impact on the success of organ transplants, especially once a patient has left the hospital environment.